| Name | Title | Contact Details |
|---|---|---|
John Connelly |
SVP, Portfolio Strategy and R&D Operations | Profile |
Day One Biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine.
Bamboo was formed to advance the work of Dr. Richard Jude Samulski, the Director of the Gene Therapy Center at the University of North Carolina (UNC), from the laboratory into human clinical trials where it could meet the requirements for drug approval. Dr. Samulski is a pioneer in the field of gene therapy. Over thirty (30) years ago, Dr. Samulski was the first person to realize the potential to use the adeno-associated virus (AAV) as a vehicle to replace a defective gene with a healthy gene. Since that time, he has re-engineered the naturally occurring virus to target delivery to certain tissues, de-target other tissues, and improve its safety. This has resulted in over twenty (20) patents related to the use of AAV for therapeutic uses. Dr. Samulski continues to lead innovation in the field of vector optimization and AAV re-engineering.
Relay has developed a proprietary software solution for stakeholders of the biopharmaceutical technology licensing and development process.
Kythera Biopharmaceuticals, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
BioStar Systems is a Kansas City, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.